MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bahouth, S. W.
Right arrow Articles by Malbon, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bahouth, S. W.
Right arrow Articles by Malbon, C. C.

Subclassification of beta-adrenergic receptors of rat fat cells: a re- evaluation

SW Bahouth and CC Malbon

Department of Pharmacological Sciences, School of Medicine, State University of New York, Stony Brook 11794-8651.

Catecholamines regulate lipolysis in rat fat cells via beta-adrenergic receptors. Recently, it has been proposed that beta-adrenergic receptors of rat fat cells are neither beta 1 nor beta 2 in character but rather an 'isoreceptor,' 'hybrid,' or 'beta 3' [Br. J. Pharmacol. 84:131-137 (1985)]. This putative receptor subtype has been envisioned as possessing an alkanolamine side-chain interaction site of beta 1 nature and an aromatic moiety interaction site of beta 2 nature. These proposals were evaluated in the present work through a reexamination of the nature of the fat cell beta-adrenergic receptor using four radioligands that differ chemically in one or both of these regions of the molecule as well as in their hydrophobicity. Equilibrium binding of agonist and of beta 1- and beta 2-subtype-selective high affinity antagonist ligands to fat cell membranes was detailed. The binding sites labeled by these ligands had the characteristics of beta 1- adrenergic receptors. The rank order of subtype-selective antagonists in competing for radioligand binding to fat cell membranes was the same as that for inhibition of agonist-stimulated cyclic AMP accumulation by these ligands. At equimolar concentrations, the beta 1-selective antagonist CGP-20712A provided a greater degree of inhibition of catecholamine-stimulated lipolysis than the beta 2-selective antagonist ICI-118,551. These results document the character of the rat fat cell beta-adrenergic receptor as solely beta 1.

Volume 34, Issue 3, pp. 318-326, 09/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Exp. Biol. Med.Home page
S. Collins, W. Cao, K. W. Daniel, T. M. Dixon, A. V. Medvedev, H. Onuma, and R. Surwit
Adrenoceptors, Uncoupling Proteins, and Energy Expenditure
Experimental Biology and Medicine, December 1, 2001; 226(11): 982 - 990.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
L. Emorine, S Marullo, M. Briend-Sutren, G Patey, K Tate, C Delavier-Klutchko, and A. Strosberg
Molecular characterization of the human beta 3-adrenergic receptor
Science, September 8, 1989; 245(4922): 1118 - 1121.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics